Guangzhou Hairui Pharmaceutical Co., Ltd. (referred to as "Hairui Pharmaceutical") is a wholly-owned subsidiary of Yangzijiang Pharmaceutical Group. Founded in 2004, it is a modern comprehensive pharmaceutical enterprise integrating R&D, production and marketing. It is located in Guangzhou High-tech Industrial Development Zone Science City has more than 380 employees and covers an area of about 110,000 square meters. At present, it has 2 drug research institutes, 4 modern production workshops and 1 automated high-bay warehouse. Since it was put into production in 2008, it has successively won the "National Torch Program Key High-tech Enterprise", "High-tech Enterprise", "National Academician Expert Workstation", "Guangdong Innovative Enterprise", "Guangzhou Innovation Benchmarking Hundred Enterprises (the first batch )” and other honorary titles.

Hairui Pharmaceutical regards R&D and innovation as the driving force for the company's development, and actively cooperates with domestic well-known scientific research institutions such as Zhongda University, Jinda University, Zhejiang University, and Chinese Academy of Sciences, and has established generic drugs, innovative drugs, traditional Chinese medicine, biological medicine and medical treatment. Five innovative R&D platforms for devices, covering cardiovascular and cerebrovascular, analgesia, endocrinology, orthopedics and other therapeutic fields, are actively promoting the industrialization of generic drugs, chemical innovative drugs, traditional Chinese medicine and biological innovative drugs, and innovative medical devices, and have undertaken 16 national , various major special projects of the province, city and district. Since 2008, the exclusive product and national key new product "Beixue Citrus Desloratadine Tablets", the exclusive product "Bai An Xin Amlodipine Benazepril Tablets (I)", the exclusive traditional Chinese medicine product, China Patent Excellence Award The product "Zhengyuan Capsules" has been successfully launched one after another, and the exclusive new drugs represented by them have remarkable curative effect and are sold nationwide. In recent years, the heavyweight varieties of Fasudil Hydrochloride Injection, Thymosin for Injection, Parecoxib Sodium for Injection, Atosiban Acetate Injection, Ticagrelor Tablets and Rivaroxaban Tablets have been launched one after another. Further enrich the pipeline of listed products.

The company regards quality as the life of the enterprise, and adheres to the quality culture of "pharmaceuticals for parents, pharmaceuticals for relatives". Two quality month activities are carried out every year; more than ten quality management (QCC) groups have been established in the front line of R&D, production and quality, of which more than 60 key research topics have won the first prize in the national pharmaceutical industry QC achievement evaluation; 2015 , 2017, 2018, 2019, 2020 five times won the International Quality Management Group Competition (ICQCC) Gold Award; the company has always been committed to continuously improving the quality assurance system, has passed ISO9001, ISO14001, OHSAS18001, ISO10012, ISO17025 and other international system certifications; The solid preparation workshop, freeze-dried powder injection workshop, traditional Chinese medicine extraction workshop, and small volume injection workshop have successively passed the new national GMP certification, of which the solid preparation workshop has passed the EU GMP certification.

Facing the future, Hairui Pharmaceutical will continue to improve the market-oriented, R&D-driven, and quality-based development model, deeply implement the three-drug development strategy of "chemical medicine, traditional Chinese medicine and biological medicine", and expand the development of innovative medical device business. , and strive to build Hai Rui into a first-class pharmaceutical enterprise in South China. Help the group to move towards the vision and goal of "becoming the strongest and world-class pharmaceutical company in China".